• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    12/28/23 1:07:18 PM ET
    $AMPE
    $ARQT
    $ATUS
    $BACK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email

    Shares of DouYu International Holdings Limited (NASDAQ:DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

    DouYu plans repurchase of up to $20 million of ordinary shares in the form of ADSS during period of up to twelve months commencing on Jan. 1, 2024.

    DouYu International shares jumped 14.2% to $0.8320 on Thursday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Nova LifeStyle, Inc. (NASDAQ:NVFY) shares jumped 204% to $4.71.
    • Cingulate Inc. (NASDAQ:CING) climbed 157.4% to $10.27. On Tuesday, Cingulate received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational product candidate for attention deficit hyperactivity disorder (ADHD).
    • Bone Biologics Corporation (NASDAQ:BBLG) gained 62.2% to $7.54.
    • SenesTech, Inc. (NASDAQ:SNES) shares climbed 50.7% to $1.30. HC Wainwright & Co. analyst Amit Dayal maintained SenesTech with a Buy, adjusting target to $3.5 from $4.
    • Microbot Medical Inc. (NASDAQ:MBOT) rose 38% to $1.8301 after the company announced the completion of its GLP pivotal pre-clinical study.
    • Sidus Space, Inc. (NASDAQ:SIDU) gained 32% to $5.81.
    • DatChat, Inc. (NASDAQ:DATS) rose 30% to $2.62. DatChat announced the release of its new AI social gaming platform and developer program for game designers and content creators.
    • SEALSQ Corp (NASDAQ:LAES) gained 25% to $1.4424. SEALSQ disclosed that its post-quantum semiconductor technology, based on cutting-edge cryptographic algorithms, is specifically designed to withstand attacks from and secure cryptocurrency transactions against the looming threat of quantum computing.
    • Ocean Biomedical, Inc. (NASDAQ:OCEA) surged 21.4% to $0.7299.
    • DSS, Inc. (NYSE:DSS) jumped 21% to $0.1477.
    • RenovoRx, Inc. (NASDAQ:RNXT) gained 20% to $1.2599.
    • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose 20% to $3.6250. The FDA recently approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older.
    • Envoy Medical, Inc. (NASDAQ:COCH) gained 17.1% to $1.98.
    • Flux Power Holdings, Inc. (NASDAQ:FLUX) rose 16.6% to $4.00.
    • Next.e.GO N.V. (NASDAQ:EGOX) shares rose 14.5% to $0.5321 after gaining 6% on Wednesday.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) gained 14.2% to $8.26. Iovance Biotherapeutics announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) shares gained 11.8% to $2.4611 after jumping 20% on Wednesday.
    • Altice USA, Inc. (NASDAQ:ATUS) rose 11.8% to $3.41 after gaining around 12% on Wednesday.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) jumped 11.4% to $3.1550.
    • Altice USA, Inc. (NYSE:ATUS) gained 10.1% to $3.36.
    • Lufax Holding Ltd (NYSE:LU) jumped 9.3% to $3.05.
    • UP Fintech Holding Limited (NASDAQ:TIGR) gained 9.2% to $4.4980.
    • TeraWulf Inc. (NASDAQ:WULF) shares gained 8.2% to $3.1150 after gaining around 30% on Wednesday.

    Losers

    • Cytosorbents Corporation (NASDAQ:CTSO) shares fell 40.2% to $0.9733. CytoSorbents released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S. and Canadian STAR-T trial.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 29.5% to $1.2691. Bluejay Diagnostics announced pricing of $3.5 million public offering of 2,692,308 shares at $1.30 per share.
    • Velo3D, Inc. (NYSE:VLD) fell 25.7% to $0.4683 after the company announced a registered direct offering.
    • Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) declined 23% to $2.0808. Meihua International Medical Technologies entered into securities purchase agreement with investors to issue and sell initial $6 million tranche in offering of $50.5 million of its securities.
    • IMAC Holdings, Inc. (NASDAQ:BACK) dipped 21.4% to $2.1206.
    • Sentage Holdings Inc. (NASDAQ:SNTG) fell 21% to $1.58. Sentage Holdings recently reported a loss of 46 cents per share in the six months ended June 30, 2023, versus a year-ago loss of 41 cents per share.
    • Airship AI Holdings, Inc. (NASDAQ:AISP) declined 17% to $2.14.
    • NeoGenomics, Inc. (NASDAQ:NEO) fell 16.4% to $17.13 after Natera won a preliminary injuction in a patent infringement lawsuit against NeoGenomics' RaDar test.
    • Baosheng Media Group Holdings Limited (NASDAQ:BAOS) fell 16.3% to $3.58.
    • Linkage Global Inc (NASDAQ:LGCB) declined 16.2% to $1.3357.
    • Bit Brother Limited (NASDAQ:BETS) fell 14.9% to $0.0114.
    • RiskOn International, Inc. (NASDAQ:ROI) fell 14.8% to $0.3661. Ault Alliance disclosed that its majority beneficially owned subsidiary, RiskOn International, expects to announce its new generative artificial intelligence platform and launch a relationship with its principal technology partner on Jan. 3, 2024.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) fell 14.6% to $4.7199. First Wave BioPharma recently announced that it entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases.
    • Hallmark Financial Services, Inc. (NASDAQ:HALL) fell 13.7% to $1.0101 after dipping 25% on Wednesday. On Dec. 26, the company announced that it intends to voluntary delist from the Nasdaq.
    • AEye, Inc. (NASDAQ:LIDR) shares fell 12.4% to $2.32 after gaining 19% on Wednesday.
    • Calliditas Therapeutics AB (NASDAQ:CALT) declined 11.6% to $25.19. Calliditas Therapeutics recently announced FDA approval of TARPEYO.
    • Wheels Up Experience Inc. (NYSE:UP) fell 10.8% to $5.12.
    • Hut 8 Corp. (NASDAQ:HUT) fell 10.1% to $16.29.
    • Iris Energy Limited (NASDAQ:IREN) dipped 9.7% to $8.64. Iris Energy recently announced that its 10 EH/s expansion program is fully funded following the completion of the targeted equity raising program.
    • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) shares fell 9.4% to $0.3031 after jumping over 40% on Wednesday.
    • Cyclo Therapeutics, Inc. (NASDAQ:CYTH) shares fell 8.6% to $1.4973. Cyclo Therapeutics announced the closing of merger with Applied Molecular Transport Inc.
    • 1847 Holdings LLC (NASDAQ:EFSH) fell 8.2% to $0.4773. 1847 Holdings said it will effect a 1-for-4 reverse split of its common shares that will become effective on Jan. 8, 2024.
    • Bridgeline Digital, Inc. (NASDAQ:BLIN) fell 5.3% to $0.8501 following the release of fourth-quarter results.

     

    Now Read This: Amazon, Adobe And 2 Other Stocks Insiders Are Selling

    Get the next $AMPE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPE
    $ARQT
    $ATUS
    $BACK

    CompanyDatePrice TargetRatingAnalyst
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    TeraWulf Inc.
    $WULF
    3/23/2026$30.00Buy
    Arete
    Hut 8 Corp.
    $HUT
    3/23/2026$136.00Buy
    Arete
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    TeraWulf Inc.
    $WULF
    2/9/2026$37.00Overweight
    Morgan Stanley
    Hut 8 Corp.
    $HUT
    2/2/2026$80.00Buy
    H.C. Wainwright
    IREN Limited
    $IREN
    1/13/2026$80.00Sell → Buy
    H.C. Wainwright
    More analyst ratings

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

    Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka's bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 millionAthyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to EsperionFinancing supports Esperion's acquisition of Corstasis Therapeutics Inc., which developed and is commercializing Enbumyst™, the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular and hepatic and renal disease NEW YORK a

    4/2/26 4:05:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. "The closing of this acquisition marks an important milestone in advancing our Vision 2040 and strengthens our commitm

    4/2/26 4:00:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Only Mach 2+ Commercial Fleet in the World Is Now Testing Reusable Hypersonic Space Systems -- and the Pentagon Is Writing the Checks

    Issued on behalf of Starfighters Space, Inc.CAPE CANAVERAL, Fla., April 2, 2026 /CNW/ -- USA News Group News Commentary — The next arms race isn't being fought on the ground. It's being fought at 45,000 feet and Mach 2, in the stratosphere where hypersonic weapons are validated, reusable space systems are tested, and the gap between the United States and its adversaries is either closed or conceded. The Pentagon knows it. Congress knows it. And the capital flowing into the commercial aerospace sector right now reflects exactly that urgency. The U.S. Space Force is operating on a

    4/2/26 2:02:00 PM ET
    $ASTS
    $FJET
    $LUNR
    Telecommunications Equipment
    Consumer Discretionary
    Air Freight/Delivery Services
    Industrial Machinery/Components

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Arete initiated coverage on TeraWulf with a new price target

    Arete initiated coverage of TeraWulf with a rating of Buy and set a new price target of $30.00

    3/23/26 8:29:37 AM ET
    $WULF
    EDP Services
    Technology

    Arete initiated coverage on Hut 8 Mining with a new price target

    Arete initiated coverage of Hut 8 Mining with a rating of Buy and set a new price target of $136.00

    3/23/26 8:29:00 AM ET
    $HUT
    Finance: Consumer Services
    Finance

    $AMPE
    $ARQT
    $ATUS
    $BACK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Welgus Howard G.

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    4/3/26 5:46:20 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Stone Warren

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    4/3/26 4:39:10 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 4 filed by Zook Anthony P.

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    4/3/26 4:38:47 PM ET
    $NEO
    Precision Instruments
    Health Care

    $AMPE
    $ARQT
    $ATUS
    $BACK
    SEC Filings

    View All

    SEC Form 424B3 filed by Flux Power Holdings Inc.

    424B3 - Flux Power Holdings, Inc. (0001083743) (Filer)

    4/3/26 9:06:57 AM ET
    $FLUX
    Industrial Machinery/Components
    Miscellaneous

    Flux Power Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Flux Power Holdings, Inc. (0001083743) (Filer)

    4/3/26 9:03:28 AM ET
    $FLUX
    Industrial Machinery/Components
    Miscellaneous

    Esperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    4/2/26 4:22:14 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Bucella Michael C. bought $19,950 worth of shares (1,338 units at $14.91), increasing direct ownership by 0.49% to 273,552 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/13/26 5:49:13 PM ET
    $WULF
    EDP Services
    Technology

    Director Bucella Michael C. bought $30,071 worth of shares (2,085 units at $14.42), increasing direct ownership by 0.77% to 272,214 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/9/26 7:31:19 PM ET
    $WULF
    EDP Services
    Technology

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Financials

    Live finance-specific insights

    View All

    The Only Mach 2+ Commercial Fleet in the World Is Now Testing Reusable Hypersonic Space Systems -- and the Pentagon Is Writing the Checks

    Issued on behalf of Starfighters Space, Inc.CAPE CANAVERAL, Fla., April 2, 2026 /CNW/ -- USA News Group News Commentary — The next arms race isn't being fought on the ground. It's being fought at 45,000 feet and Mach 2, in the stratosphere where hypersonic weapons are validated, reusable space systems are tested, and the gap between the United States and its adversaries is either closed or conceded. The Pentagon knows it. Congress knows it. And the capital flowing into the commercial aerospace sector right now reflects exactly that urgency. The U.S. Space Force is operating on a

    4/2/26 2:02:00 PM ET
    $ASTS
    $FJET
    $LUNR
    Telecommunications Equipment
    Consumer Discretionary
    Air Freight/Delivery Services
    Industrial Machinery/Components

    SIDUS SPACE REPORTS FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

    CAPE CANAVERAL, Fla., April 1, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) (the "Company" or "Sidus"), an innovative space and defense technology company, announced its financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. "2025 was a pivotal year for Sidus as we continued executing our long‑term strategy to build vertically integrated space and defense technology platforms," said Carol Craig, Founder and CEO of Sidus Space. "We expanded our on‑orbit capabilities with the successful launch and commissioning of Li

    4/1/26 6:01:00 AM ET
    $MTEK
    $SIDU
    Telecommunications Equipment
    Telecommunications

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    SEALSQ Signs Letter of Intent to Acquire 100% of Miraex, a Swiss Quantum Interconnect Platform Company

    Geneva, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Strategic Acquisition via the SEALSQ Quantum Fund Strengthens its Quantum Vertical Stack SEALSQ Corp (NASDAQ:LAES) ("SEALSQ" or the "Company"), a subsidiary of WISeKey International Holding Ltd (NASDAQ:WKEY, SIX: WIHN)) and a leader in post-quantum semiconductor and cybersecurity solutions, today announced that it has signed a Letter of Intent ("LOI") to acquire 100% of the equity interest of Miraex SA ("Miraex"), a developer of photonics-based quantum interconnect solutions that bridge quantum processors and quantum networks, headquartered at the EPFL Innovation Park in Ecublens, Switzerland. The LOI provides for a 60-day exclusivi

    3/24/26 9:20:00 AM ET
    $LAES
    $WKEY
    Semiconductors
    Technology
    EDP Services

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IREN Appoints John Gross as Chief Innovation Officer

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ:IREN) ("IREN") today announced the appointment of John Gross as Chief Innovation Officer, a newly established role responsible for leading engineering standards, thermal architecture, and commissioning across IREN's next-generation data centers. Mr. Gross is a globally recognized leader in data center engineering, with two decades of industry experience and deep expertise in high-density and liquid-cooled data center design. He serves as Vice Chair of committees within ASHRAE (American Society of Heating, Refrigerating and Air-Conditioning Engineers), which develops global standards for high-density and liquid-cooled data ce

    2/17/26 5:00:50 AM ET
    $IREN
    EDP Services
    Technology

    $AMPE
    $ARQT
    $ATUS
    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bridgeline Digital Inc.

    SC 13G/A - Bridgeline Digital, Inc. (0001378590) (Subject)

    12/13/24 11:31:58 AM ET
    $BLIN
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by DSS Inc.

    SC 13D/A - DSS, INC. (0000771999) (Subject)

    12/12/24 9:56:52 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Lufax Holding Ltd

    SC 13D/A - Lufax Holding Ltd (0001816007) (Subject)

    12/9/24 6:12:27 AM ET
    $LU
    Finance: Consumer Services
    Finance